6.1 Signaling Principles and Intracellular Receptors

Core Explanation

Cell-to-cell communication proceeds through a conserved sequence: signal → receptor → transduction → response. The mode of signaling depends on the distance the signal molecule travels.

Modes of intercellular signaling:

• Endocrine: Hormones secreted into the bloodstream travel long distances to target cells bearing cognate receptors (e.g., insulin, epinephrine, cortisol).
• Paracrine: Signal molecules diffuse locally through the extracellular fluid to neighboring cells (e.g., growth factors, prostaglandins, neurotransmitters acting extrasynaptically).
• Autocrine: A cell secretes a signal that binds to receptors on its own surface, reinforcing its own state (e.g., T-cell interleukin-2 release driving clonal expansion; cancer cells driving their own proliferation).
• Synaptic: Neurons release neurotransmitters across a specialized ~20–40 nm synaptic cleft onto a postsynaptic target. This combines extreme speed with spatial precision.
• Contact-dependent (juxtacrine): A membrane-bound signal on one cell engages a receptor on an adjacent cell without any diffusible intermediate (e.g., Delta-Notch signaling, immune synapse formation).

Six core signaling principles underlie all of these modes.

1. Specificity: Achieved by precise molecular complementarity between signal and receptor. A given cell only responds if it expresses the appropriate receptor — the same hormone can trigger different responses in different cell types.

1. Amplification: A single receptor–ligand binding event can trigger a cascade of enzymatically catalyzed steps, each activating many downstream targets. One epinephrine molecule bound to a β-adrenergic receptor can, through G-protein → adenylyl cyclase → cAMP → PKA → phosphorylase kinase → glycogen phosphorylase, ultimately mobilize ~10⁸ glucose molecules.

1. Integration: Cells simultaneously receive multiple signals and must compute a net response. Signal integration occurs when two pathways converge on a shared effector, allowing the cell to respond only when both inputs are present (coincidence detection) or to sum graded inputs.

1. Desensitization / Adaptation: Prolonged exposure to a signal often diminishes the response. Mechanisms include receptor phosphorylation (uncoupling from downstream effectors), receptor internalization, and degradation of second messengers by phosphodiesterases.

1. Crosstalk: Signaling pathways are not linear isolation chambers; components of one pathway modulate another. For example, cAMP-dependent PKA can phosphorylate and modulate components of the MAPK cascade, and Ca²⁺/calmodulin can regulate adenylyl cyclase isoforms.

1. Feedback: Outputs regulate upstream steps. Negative feedback (e.g., PKA phosphorylating the β-adrenergic receptor to promote β-arrestin binding) provides homeostatic restraint. Positive feedback (e.g., Ca²⁺-induced Ca²⁺ release via IP3 receptors in fertilization) can generate switch-like, all-or-none responses.

Molecular Components

Intracellular / Nuclear Receptors: Steroid hormones (cortisol, estradiol, testosterone, aldosterone), thyroid hormones, retinoids, and vitamin D are hydrophobic enough to cross the plasma membrane by simple diffusion. Their receptors reside in the cytoplasm or nucleus, often held in an inactive state by chaperone complexes (Hsp90, immunophilins). Ligand binding causes a conformational change that releases chaperones, exposes nuclear localization signals, promotes dimerization, and enables DNA binding. The ligand–receptor complex binds hormone response elements (HREs) in promoter/enhancer regions and recruits coactivators (e.g., SRC/p160 family) or corepressors to modulate transcription. These are regulated transcription factors — the signal is the hormone, the transduction step is receptor activation, and the response is a change in gene expression. This mode of signaling is inherently slower than second-messenger cascades (hours vs. seconds) but produces sustained cellular reprogramming.

Nitric Oxide (NO): NO is a small, diffusible free-radical gas synthesized from arginine by nitric oxide synthase (NOS) isoforms. It diffuses freely across membranes and acts in a paracrine fashion. Critically, NO does NOT act through the nuclear receptor superfamily. Its canonical receptor is soluble guanylyl cyclase (sGC), a cytosolic hemoprotein. NO binds the ferrous heme iron of sGC, inducing a conformational change that activates the catalytic domain to convert GTP → cGMP. The rise in cGMP activates protein kinase G (PKG), which phosphorylates targets including smooth muscle myosin light-chain phosphatase (causing vasodilation). cGMP also gates ion channels directly. Phosphodiesterase-5 (PDE5) terminates the signal by hydrolyzing cGMP — famously targeted by sildenafil (Viagra).

Step-by-Step Mechanism

1. Signal generation: A stimulus triggers synthesis/release of the signaling molecule (e.g., ACTH stimulates cortisol release from the adrenal cortex).
2. Transport: The signal travels by diffusion, bulk flow, or active transport to the target cell.
3. Receptor binding: The signal binds with high affinity (Kd typically nM–µM range) and specificity. For intracellular receptors, the ligand crosses the membrane and binds in the cytoplasm or nucleus. For NO, it diffuses into the target cell and binds sGC.
4. Transduction: The binding event is converted into an intracellular chemical change — transcription factor activation for nuclear receptors; cGMP synthesis for NO.
5. Effector activation: Transcription of target genes (nuclear receptors) or phosphorylation of downstream targets (PKG).
6. Response: Measurable cellular change — altered metabolism, secretion, proliferation, differentiation, or apoptosis.
7. Termination: Ligand degradation, receptor desensitization/inactivation, or second-messenger hydrolysis.

Regulation

• Receptor availability: Up- or downregulation of receptor expression tunes sensitivity. Chronic high cortisol downregulates glucocorticoid receptor expression.
• Chaperone control: Hsp90 maintains nuclear receptors in a ligand-competent but inactive state; its inhibition (e.g., by geldanamycin) accelerates receptor degradation.
• Coregulator recruitment: The balance of coactivators and corepressors determines whether a liganded nuclear receptor activates or represses transcription. Tamoxifen-bound estrogen receptor recruits corepressors in breast tissue, antagonizing estrogen-driven proliferation.
• cGMP regulation: sGC activity is modulated by the redox state of its heme iron; PDE5 rapidly hydrolyzes cGMP. NO itself has a short half-life (~seconds) in biological fluids due to scavenging by oxyhemoglobin and reaction with superoxide.
• Feedback: Cortisol binds the glucocorticoid receptor, which transcriptionally represses pro-opiomelanocortin (POMC) expression in the anterior pituitary, reducing ACTH and thus cortisol synthesis — a classic negative feedback loop (the HPA axis).

Energy

• Signal synthesis: ATP- and NADPH-dependent (e.g., arginine → NO by NOS requires NADPH, FAD, FMN, BH₄, and O₂).
• Transcription/translation: Gene expression following nuclear receptor activation is energetically expensive — RNA and protein synthesis consume substantial ATP and GTP.
• cGMP cycle: Each round of GTP → cGMP → GMP costs one high-energy phosphate bond (γ-phosphate of GTP).

Experimental Evidence

• Nuclear receptors: Radiolabeled [³H]-dexamethasone was shown to accumulate in target cell nuclei (Munck & Brinck-Johnsen, 1968). DNA footprinting and ChIP-seq have since identified specific HREs across the genome.
• NO/sGC/cGMP: Furchgott, Ignarro, and Murad shared the 1998 Nobel Prize. Furchgott demonstrated that acetylcholine-induced vasodilation required an intact endothelium releasing an "endothelium-derived relaxing factor" (EDRF), later identified as NO. Ignarro and Murad showed NO activates sGC to produce cGMP, and hemoglobin (which scavenges NO) blocked the response.

Disease / Clinical Relevance

• Nuclear receptor defects: Androgen receptor mutations cause androgen insensitivity syndrome (AIS). Glucocorticoid resistance syndromes involve GR mutations or altered coregulator expression.
• NO dysregulation: Endothelial NOS dysfunction contributes to hypertension and atherosclerosis. In septic shock, massive iNOS induction causes pathological vasodilation. PDE5 inhibitors (sildenafil, tadalafil) treat erectile dysfunction and pulmonary hypertension by prolonging cGMP signaling.
• Pharmacology: ~10–15% of FDA-approved drugs target nuclear receptors (e.g., thiazolidinediones → PPARγ for diabetes; tamoxifen → ER for breast cancer).

High-Yield Summary

• Five signaling modes: endocrine (bloodstream), paracrine (local diffusion), autocrine (self), synaptic (specialized cleft), contact-dependent (membrane-bound signal).
• Six principles: specificity, amplification, integration, desensitization, crosstalk, feedback.
• Nuclear receptors are ligand-activated transcription factors; responses are slow but sustained.
• NO signals through soluble guanylyl cyclase → cGMP, NOT through nuclear receptors.
• cGMP activates PKG and is hydrolyzed by PDE5; this pathway mediates vasodilation.

Practice Questions

Q1: A researcher treats cultured cells with a membrane-impermeable fluorescent derivative of a peptide hormone and observes fluorescence only on the cell surface. What class of receptor does this hormone likely activate, and what must happen for the signal to propagate into the cell?

A1: The hormone activates a cell-surface receptor (likely a GPCR or RTK) because it cannot cross the membrane. Signal propagation requires transmembrane transduction — ligand binding on the extracellular side triggers a conformational change that activates intracellular signaling domains (e.g., G-protein coupling, kinase activation) to generate second messengers or phosphorylation cascades.

Q2: Why does cortisol take hours to produce a physiological effect, whereas epinephrine acts within seconds?

A2: Cortisol binds the intracellular glucocorticoid receptor, a transcription factor; the response requires transcription, mRNA processing, translation, and protein accumulation — a slow process. Epinephrine binds cell-surface β-adrenergic receptors, activating pre-existing second-messenger cascades (cAMP/PKA) and enzymes (glycogen phosphorylase), producing effects in seconds.

Q3: A patient takes sildenafil (Viagra) for erectile dysfunction. Explain the molecular mechanism, including the relevant second messenger, its synthetic enzyme, its target, and how sildenafil prolongs signaling.

A3: Nitric oxide (NO) released from nitrergic nerves and endothelial cells diffuses into vascular smooth muscle and activates soluble guanylyl cyclase (sGC), which synthesizes cGMP from GTP. cGMP activates protein kinase G (PKG), which phosphorylates targets that reduce intracellular Ca²⁺ and promote smooth muscle relaxation → vasodilation → erection. PDE5 normally hydrolyzes cGMP to terminate the signal. Sildenafil inhibits PDE5, prolonging the cGMP signal and sustaining vasodilation.

Common Misconceptions

• ❌ "NO acts like a steroid hormone by binding nuclear receptors." → NO binds and activates soluble guanylyl cyclase, a cytosolic enzyme, increasing cGMP.
• ❌ "All signaling requires cell-surface receptors." → Hydrophobic signals (steroids, thyroid hormone, NO) access intracellular targets directly.
• ❌ "A given signal always produces the same response." → The response depends entirely on the receptor and downstream machinery expressed in the target cell. Acetylcholine contracts skeletal muscle (nicotinic receptor) but relaxes cardiac muscle (muscarinic receptor).